Literature DB >> 31538188

Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients.

Kristin N Grimsrud1, Kelly M Lima1, Nam K Tran1, Tina L Palmieri2.   

Abstract

Opioids are essential first line analgesics for pain management after burn injury. Opioid dosing remains challenging in burn patients, particularly in children, due to the immense variability in efficacy between patients. Opioid pharmacokinetics are altered in burned children, increasing variability and obviating dosing regimens extrapolated from adult-data. The present study aimed to characterize variability in fentanyl pharmacokinetics and identify significant contributors to variability in children with ≥10% total body surface area burn requiring fentanyl during routine wound care. We recorded patient demographics and clinical data. Blood samples were collected following fentanyl administration for pharmacokinetics at time 0, 30, 60, 120, and 240 minutes on day of admission and repeated on days 3 and 7. Serum fentanyl concentrations were quantified using tandem liquid chromatography mass spectrometry. Population analysis was used to estimate pharmacokinetics parameters. Fourteen patients, 1.2-17 years, with burns from 10-50.5% were included in analysis. A two-compartment model with body weight as a covariate best described fentanyl pharmacokinetics for the overall population. The population clearance and intercompartmental clearance were 7.19 and 2.16 L/hour, respectively, and the volume of distribution for the central and peripheral compartments was 4.01 and 25.1 L, respectively. Individual patient parameter estimates had extensive variability. This study confirmed the high variability in pediatric burn patient fentanyl pharmacokinetics and demonstrates similarities and differences to other populations reported in literature. Further research is needed with a larger number of patients to extensively investigate the impact of burns, genetic polymorphisms, and other factors on fentanyl efficacy and patient outcomes. © American Burn Association 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31538188      PMCID: PMC7456975          DOI: 10.1093/jbcr/irz144

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.819


  24 in total

Review 1.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

2.  Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery.

Authors:  Sara L Van Driest; Matthew D Marshall; Brian Hachey; Cole Beck; Kim Crum; Jill Owen; Andrew H Smith; Prince J Kannankeril; Alison Woodworth; Richard M Caprioli; Leena Choi
Journal:  Br J Clin Pharmacol       Date:  2016-04-15       Impact factor: 4.335

3.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature.

Authors:  Gary Ginsberg; Dale Hattis; Babasaheb Sonawane; Abel Russ; Prerna Banati; Mary Kozlak; Susan Smolenski; Rob Goble
Journal:  Toxicol Sci       Date:  2002-04       Impact factor: 4.849

4.  Patient-controlled analgesia with fentanyl for burn dressing changes.

Authors:  Smita Prakash; Tazeen Fatima; Mridula Pawar
Journal:  Anesth Analg       Date:  2004-08       Impact factor: 5.108

5.  Age and fentanyl pharmacokinetics.

Authors:  J B Bentley; J D Borel; R E Nenad; T J Gillespie
Journal:  Anesth Analg       Date:  1982-12       Impact factor: 5.108

6.  CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.

Authors:  Sarah J Woolsey; Sara E Mansell; Richard B Kim; Rommel G Tirona; Melanie D Beaton
Journal:  Drug Metab Dispos       Date:  2015-07-31       Impact factor: 3.922

7.  A Retrospective Analysis of Clinical Laboratory Interferences Caused by Frequently Administered Medications in Burn Patients.

Authors:  Zachary Godwin; Kelly Lima; David Greenhalgh; Tina Palmieri; Soman Sen; Nam K Tran
Journal:  J Burn Care Res       Date:  2016 Jan-Feb       Impact factor: 1.845

8.  Fentanyl clearance and volume of distribution are increased in patients with major burns.

Authors:  Taehyung Han; Jerold S Harmatz; David J Greenblatt; J A Jeevendra Martyn
Journal:  J Clin Pharmacol       Date:  2007-04-11       Impact factor: 3.126

9.  Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study.

Authors:  Kristin N Grimsrud; Xenia Ivanova; Catherine M Sherwin; Tina L Palmieri; Nam K Tran
Journal:  J Burn Care Res       Date:  2019-01-01       Impact factor: 1.845

Review 10.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

View more
  1 in total

1.  Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population.

Authors:  Michael L Williams; Prince J Kannankeril; Joseph H Breeyear; Todd L Edwards; Sara L Van Driest; Leena Choi
Journal:  Clin Pharmacol Ther       Date:  2022-01-03       Impact factor: 6.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.